Abstract: Provided is a pixel circuit, a display panel, and a display device. The pixel circuit includes a light-emitting unit, a drive unit, and a control unit. A first light-emitting element and a second light-emitting element of the light-emitting unit are electrically connected with the control unit simultaneously. The drive unit is configured to send a data signal to the light-emitting unit to drive the same to emit light.

Abstract: A wearable device includes a screen, a first electrode, a second electrode, and a circuit board. The screen and the second electrode are mounted on a housing. The first electrode is coupled to the screen and does not shield a display region of the screen, and the first electrode and the second electrode are electrically coupled by the circuit board. The first electrode has a first surface, the second electrode has a second surface, and the first surface and the second surface are configured to contact a human body of a wearer.

Abstract: This application provides a wearable device. The wearable device includes a bearing body and a Bluetooth headset. An accommodating slot is disposed on the bearing body, a first locking component is disposed on the Bluetooth headset, and a second locking component is disposed on the bearing body. The Bluetooth headset is accommodated in the accommodating slot. The first locking component can be locked with the second locking component. The Bluetooth headset includes an operation portion. The operation portion is configured to: unlock the first locking component and the second locking component, and push the unlocked Bluetooth headset out of the accommodating slot. The wearable device in this application can directly accommodate the Bluetooth headset, to provide more convenience to a user.

Abstract: The disclosure is directed to compounds that bind to a target RNA molecule, such as a TPP riboswitch, compositions comprising the compounds, and methods of making and using the same. The compounds contain two structurally different fragments that allow for binding with the target RNA at two different binding sites thereby producing a higher affinity binding ligand compared to compounds that only bind to a single RNA binding site.

Abstract: This application provides a wearable device. The wearable device includes a bearing body and a Bluetooth headset. An accommodating slot is disposed on the bearing body, a first locking component is disposed on the Bluetooth headset, and a second locking component is disposed on the bearing body. The Bluetooth headset is accommodated in the accommodating slot. The first locking component is locked with the second locking component. The Bluetooth headset includes an operation portion. The operation portion is configured to: unlock the first locking component and the second locking component, and push the unlocked Bluetooth headset out of the accommodating slot. The wearable device in this application may directly accommodate the Bluetooth headset, to provide more convenience to a user.

Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.

Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.

Abstract: The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

Abstract: A battery, a battery assembly, and a user equipment are disclosed. The battery includes a circuit board and a cell. The circuit board includes a first contact, a second contact, a third contact, a fourth contact, a battery management module, and a control switch. The first contact reports a capacity of the cell in the battery, or in the battery and a cascaded battery to an upper-level battery or an electricity load; the second contact receives and output the capacity of the cell in the cascaded battery; when the control switch is opened, the third contact is connected to the cell in the battery to charge or discharge the cell in the battery; when the control switch is closed, the fourth contact is connected to the third contact; and the battery management module triggers opening or closing of the control switch.

Abstract: Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof.

Abstract: The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

Abstract: Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate.